AgenT-biotech
The Start-up Slams were won by AgenT-biotech, represented by Baptiste Billoir, in the CNS category.
About the project: AgenT is revolutionizing Alzheimer’s care by unlocking the future of precision medicine with our groundbreaking multi-omics blood tests, B-HEALED & B-AHEAD, enabling early and precise detection in pre-dementia stages.
Merck Group is awarding a special prize to the best start-up working on a biopharmaceutical therapeutic: The Merck Advance Biotech Grant Award.
This prize includes:
• €30,000 to be used towards Merck’s Bioprocessing technologies, Process Development Consultation & Services
• 2 hours of consultation time with M ventures
Congratulations ByoRNA, represented by Pascal Viguié, for winning this Merck Special Prize!
The Start-up Slams showcase young promising companies seeking to raise a seed or a Series A financing round.
Sponsored by: 
They pitched at BioFIT 2023:
ONCOLOGY
ORAKL ONCOLOGY 
Cancer | Techbio | Drug discovery and development
NASASBIOTECH 
Glioblastoma | Medical Device | Treatment
CASINVENT PHARMA 
Targeted therapy & resistance | Pancreatic cancer Gemcitabine | AML Venetoclax resistance
GLIOCURE
Anti-mitotic peptide | Taxane resistant tumors | TUBB3
REACT THERAPEUTICS
Oncology | Multi-Drug Resistance | New Chemical Entities
ONCOSEMA
Cancer monitoring | Circulating Tumor Cells | Blood test for oncology
DRUG DISCOVERY
URANIA THERAPEUTICS
Genetic disease | Cancer | Small molecule
INFLAMMATION
SURVIVX 
Sepsis | Immunomodulation | Adjuvant
PHIALOGICS
Autoimmune disease | Biologics | Immune tolerance
NUMA HEALTH
Preventive medicine | Personalized medicine | Bio-analytics
PERIOTRAP PHARMACEUTICALS 
Microbiome | Small molecule | Healthcare
CNS
AMYL THERAPEUTICS 
Neurodegenerative diseases | Amyloidosis | Multi-targets binding
INNOVADE THERAPEUTICS
Depression | Rapid Acting Antidepressant | Synaptic Plasticity
AGENT
Alzheimer’s Disease | Blood Test | Precision Medicine
MEDJEDUSE
Traumatic spinal cord injury | Tissue engineering biomaterial | Sensory-motor recovery
LACTABICO
Peptides | Anxiety disorders | Metabolic disorders
DRUG DISCOVERY
STH BIOTECH
Bioproduction | Therapeutic cannabis| Metabolic engineering
REFOXY PHARMACEUTICALS
Idiopathic Pulmonary Fibrosis | Ageing-diseases | FOXO3
ORIA BIOSCIENCE
New intracellular targets | Organelles | High Throughput Screening
GENERARE
Synthetic biology | Bioinformatics | Natural products
DIAGNOSTIC
MARX BIOTECHNOLOGY 
Health Care | Life Sciences | Diagnostics
CARDIOVASCULAR & METABOLIC DISEASES
EXADEX-INNOV
Chronic metabolic diseases | Obesity | Cell therapy
TECHNOLOGY PLATFORMS
SEABELIFE BIOTECH
First in class small molecule | Cell death inhibitor | Plateform Technology
EVERSYN
Biobetters & Biosimiliars | Glycoengineering | Oligosaccharides
MT-ACT
NCEs | First in class | Cardiovascular
EPHYRA 
Sponge RNA | miRNA | Snowflake RNA (sfRNA)
DRUG DELIVERY
NANOREVIV
Drug Delivery Platform | Antibiotics | Bacterial resistances
APILLET 
Enteric encapsulation/coating | Nutraceuticals & pharmaceutica | Natural materials
THERALIA 
Drug delivery | Personalized medicine | Targeted antibiotics
IMMUNOLOGY
BYORNA
RNA | Vaccine| Cancer
LOVALTECH
Nasal vaccines | Universal protein vaccine | Mucosal immunity
IMMUNEWATCH
Immunology | T cells | AI
ONCO-IMMUNOLOGY
MODIBLAST PHARMA
Leukemia | Immunomodulation | Dendritic Cell
ONCOBONE VENTURES
Bone metastasis | Immunotherapy | Preclinical testing
San Raffaele University and Research Hospital
The most promising technology award went to the San Raffaele University and Research Hospital with their CAR/TCR T Cell Therapy project.
“I was delighted to participate to the Collaborative and Licensing Opportunity pitch session. The session provided a valuable platform to showcase our projects and explore potential collaborations. The engagement and interest from committee members and participants were truly encouraging, and I believe this will pave the way for exciting partnerships in the near future.
I am pleased with the productive outcomes of the BioFIT event, especially the significant number of B2B meetings I attended. These meetings were instrumental in fostering connections, exchanging ideas, and exploring collaborative opportunities. Overall, BioFIT proved to be an invaluable platform for networking and exploring synergies within the industry. I am grateful for the opportunity and optimistic about the potential partnerships that may stem from these interactions.” Marco Catucci, Research Business Developer, Ospedale San Raffaele.
The Collaborative and Licensing Opportunity Presentations showcase early-stage technologies from TTOs, universities, research institutes and companies.
Co-organised by: 
They pitched at BioFIT 2023:
INFECTIOUS DISEASES
NANOREVIV – STAPH-EX
Lipid nano-capsules Platform | Antibiotics | Bacterial Resistance
AATEC MEDICAL – AAT
Inflammation | Respiratory | Inhalation
LILLE UNIVERSITY/ INSERM – CANDIDIASIS DIAGNOSIS
Candidiasis | Diagnosis | Monoclonal antibody
BIOASTER – COLICIN/IMMUNITY TECHNOLOGY
Multiplexing | Immunoassay | Diagnostic
G.ST ANTIVIRALS – 2-DEOXYGLUCOSE TREATMENT 
Respiratory viral infections | 2-deoxyglucose | Spray and nebulizer
CELL & GENE THERAPY
FONDAZIONE TELETHON ETS – 3D CELL CULTURE 
3D cell culture | Gene Therapy | Nichioids
FONDAZIONE TELETHON ETS – CASWITCH
Gene circuit | Biosensor | Inducible gene expressio (no leakiness)
FONDAZIONE TELETHON ETS – IL-1RA GENE THERAPY
Gene Therapy | IL-1RA | Systemic Autoinflammatory Diseases
FONDAZIONE TELETHON ETS – TOLEROGENIC DC TECHNOLOGIES
Tolerogenic Dendritic Cells | Autoimmune diseases | Cell Therapy
CNS
CILCARE – AUDITORY MEASUREMENTS
Auditory | Biomarker | CNS
KVANTIFY – DRUG DISCOVERY TOOL
Drug discovery | CNS | Small molecule
UNIVERSITY OF ANTWERP – INEUROVIR
Viral infection | Neurodegenerative | High throughput screening
IOCB TECH
Neurosteroids | Neuropathic pain | Epilepsy
ONCOLOGY
ERASMUS MC – CHROMSTRETCH
DNA replication | Replication stress | Cancer
MINOS BIOSCIENCES – SINGLE – CELL ANALYSIS
Oncology / Immuno-oncology | Single-cell functional analysis | Multi-omic analysis
SAN RAFFAELE UNIVERSITY AND RESEARCH HOSPITAL – CAR/TCR T CELL THERAPY
CAR | Adoptive cell therapy | Cancer
UNIVERSITY OF GRENOBLE ALPES (UGA) – TERG
Glioma | Antisense oligonucleotide | Sensitization
AKRIBION GENOMICS – G-DASE E
Programmable anti-cancer drugs | RNA biomarkers | Head & neck cancer
The Award for the most Innovative Animal Health Project goes to:
the LUCKY project from SATT PARIS SACLAY
Stéphane Gobron, Project Manager in Life Sciences, is the winner of this year’s edition of the Animal Health Presentations, with its project LUCKY from the SATT Paris Saclay.
The project highlights a specific strain of Levilactobacillus brevis, named LBH1073, which exhibits unique anti-proliferative activities and anti-cancer properties.
Exceptionnally this year, the jury decided to award another project with a special jury prize: VETBIOLIX, represented by Matthieu Dubruque, Managing Director.
The Animal Health Presentations focus on innovations in relation to animal well-being and health.
Co-organised by: 
They pitched at BioFIT 2023:
ANIMAL HEALTH
VETBIOLIX
Cathepsin-K Inhibitor | Adenosin-A3 Agonist | 5-HT4 Agonist
MI:RNA
Blood microRNA | Artificial Intelligence | Early disease diagnosis
VIRCO 
Antiviral | Corrol | Poxyvirus / Herpes virus
MYOMU
Sarcopenia | Natural compound | NCE
LUCKY
Probiotic | Anti-proliferative | Pets
Alexandre Breda, Biotech Start-up Manager, Eurasanté
Gary Breit, CEO, Breit Ideas LLP 
Vincent Brichard, Venture Partner, EQT Life Sciences
Zuzanna Brzosko, Senior Director, Corporate Strategy & External Innovation, Eli Lilly and Company
Ivan Burkov, Principal, Inkef
Florence Dal Degan, Senior Director, External Innovation, Rare Diseases and Neuroscience, Ipsen
Isabelle Dupin-Roger, Director, R&D External Innovation I Neuroscience and Immuno-inflammation, Servier
Dorothée Gueras Tricart, Head of Biotech division, Eurasanté
Monique Guis, External Innovation Immunology Director, Sanofi
Frank Hensel, Principal, High-Tech Gründerfonds
Dmitrij Hristodorov, Partner, Forbion
Lydia Kalafateli, Venture Developer, NLC Health
Alexandre Laly, Customer Application Consultant – Emerging Biotech, Merck
Esther Lange, Industry Liaison Manager, Ascenion
Marie-Ange N’Zoutani, Head of Acceleration office Sanofi Partnering, Sanofi
Richard Reschen, Associate Director, BD&L Europe, MSD
Olaf Ritzeler, BD&L, Director, Rare Diseases External Innovation / GLOBAL, Sanofi
Corinne Szilagyi, Senior Partner, Biotech Développement Conseils & Member of the Business Development Committee, France Biotech
Kristin Thompson, VP, Chief Business Officer, eureKARE
Joachim Vogt, Director, Search and Evaluation, Western Europe, AbbVie
Ulrich Zugel, Senior Director Emerging Science & Innovation Lead – Inflammation & Immunology Europe, Pfizer
Jean-Christophe Audonnet
Jean-Louis Hunault, President, SIMV
Theo Kanellos, Director Business Development and comercial Alliances, Zoetis 
Jean-Pascal Marc, Corporate Product Innovation Director, Virbac
Edouard Timsit, Senior Innovation Scientist, Ceva Santé Animale
